Vertex Names Former Boston Scientific CFO Daniel Brennan To Its Board, Raising Seats To Eleven
Brennan, a CPA, also joins the Audit and Finance Committee and receives a $400,000 restricted stock unit award vesting in October 2027.
Vertex Pharmaceuticals appointed Daniel Brennan, Boston Scientific's former chief financial officer, to its board on Tuesday, expanding the board from ten members to eleven, according to an 8-K filing. Brennan also joined the board's Audit and Finance Committee.
What the 8-K says
Brennan was Boston Scientific's executive vice president and chief financial officer from January 2014 until he retired in June 2025, the filing says. Before that he was senior vice president and corporate controller from 2010 through 2013, and held finance roles there from 1996 through 2009.
He has sat on the board of Waters Corporation, a maker of analytical instruments and software, since November 2022. He joined the board of Madrigal Pharmaceuticals in August 2025. He previously served on the board of Nuance Corporation until Microsoft acquired it in March 2022.
Brennan holds a B.S. in Finance and Investments and an M.B.A. from Babson College, and he is a certified public accountant.
On joining, he received a $400,000 restricted stock unit award that vests in October 2027. The filing says Vertex has no transactions with Brennan that it would have to report under Item 404(a) of Regulation S-K. It also says no arrangement or understanding with anyone else led to his appointment.
What it changes
The board gains a seat rather than replacing a director, and the new member brings accounting credentials to the audit committee. In the company's release, Brennan is credited with more than 35 years of finance experience at healthcare companies, including more than 25 years at Boston Scientific.
Vertex Executive Chairman Jeffrey Leiden said Brennan's "extensive financial leadership experience and deep understanding of global healthcare businesses will bring an important perspective to the Vertex Board."
Vertex shares closed at $514.65 in Tuesday trading, up about 2.5% at the close. The filing was accepted at 4:09 p.m. ET, after the close.
Brennan's restricted stock units vest in October 2027, a year after the appointment.
Sources
- 8-K Filing — VERTEX PHARMACEUTICALS INC / MA (VRTX) — SEC EDGAR
- Vertex Appoints Daniel Brennan to its Board of Directors — businesswire.com